BioStock: Chordate Medical's CEO on CE marking in chronic migraine

Chordate Medical has received a CE marking for K.O.S for the treatment of chronic migraine, meaning that the product can now be sold and marketed within the EU. The CE marking, which is a very important milestone for the company, got approved one year earlier than projected. BioStock contacted Anders Weilandt, Chordate Medical’s CEO, to find out what the CE marking means for the company.

Read the full article at biostock.se:

https://www.biostock.se/en/chordate-medicals-ceo-on-ce-marking-in-chronic-migraine/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se